Related Experiment Video

Updated: Aug 14, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

[Tyrosine kinases. New target of anticancer therapy]

Ireneusz Majsterek1, Dariusz Pytel, Janusz Błasiak

  • 1Katedra Genetyki Molekularnej Uniwersytetu Lódzkiego, Lódź.

Postepy Biochemii
|December 31, 2005
PubMed

Insights

New cancer drugs targeting specific tyrosine kinases show promise. Herceptin and STI571 offer clinical success in breast cancer and leukemia, respectively, highlighting the potential of kinase inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Recent clinical studies have focused on novel drug development for targeted cancer therapies.
  • Specific receptor tyrosine kinases are implicated in various cancer types.

Purpose:

  • To review the clinical success of targeted tyrosine kinase inhibitors.
  • To emphasize the importance of understanding oncogenic activation mechanisms for developing new anticancer drugs.

Summary:

  • Herceptin, a monoclonal antibody, improves survival in Her2/neu positive metastatic breast cancer.
  • STI571, a small molecule inhibitor, shows significant clinical responses in BCR/ABL positive chronic myeloid leukemia and c-Kit positive gastrointestinal stromal tumors.
  • The success of these inhibitors underscores the need for further research into kinase function and inhibition.

Impact:

  • Demonstrates the clinical efficacy of targeted therapies in oncology.
  • Stimulates further research into the structure, function, and inhibition of oncogenic tyrosine kinases.
  • Provides a foundation for developing next-generation kinase inhibitors for cancer treatment.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...